Gadolinium Contrast Dye Lawsuits

Approximately 200 million people have received a gadolinium-based contrast agent for MRI testing, but it does not appear that many were aware of the risk of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy. The side effects associated with Gadolinium Contrast Dye include:

  • Thickening of the Skin
  • Skin Sloughing
  • Joint Disabilities
  • Limited Mobility
  • Connective Tissue Disorders
  • Fibrosis of the diaphragm, muscles, abdomen and lungs
  • Kidney Dysfunction
  • Death

Prior to 2007, there were a high number of adverse event reports submitted to the FDA showing a link between Gadolinium Contrast Dye and nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy. By mid 2007, the FDA demanded a black box warning be placed on the packaging of Gadolinium Contrast Dye. This is because there were continued reports of people that suffered a slow, painful deterioration of their health due to nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy.

Gadolinium Contrast Dye is manufactured by several companies, including: Bayer Healthcare, Bracco, Covidien, GE Healthcare, and Mallinckrodt. It appears that the manufacturers were aware of the risks at a time that would have prevented injury for many. The dye was not further evaluated for safety and efficacy until recently. In December of 2009, FDA advisory panel members found that Bayer's Magnevist, Covidien's Optimark and General Electric's Omniscan appeared to pose a greater risk of NSF when compared to other contrast dye agents.

Consumers may not be aware that they have received Gadolinium Contrast Dye. Information provided about contrast dye is usually presented during an informed consent process before an MRI test. This information includes a list of side effects that should be reported to a physician if one occurs. In the informed consent documents, there is a signature page which allows for your agreement to proceed with the procedure in light of the risks. It is not known if the risk of nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy is displayed on the forms that people complete at all MRI testing facilities. In addition, consumers may not understand the seriousness of the risk associated with Gadolinium Contrast Dye and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy.

Mr. Burton Padove is privileged to represent people nationwide that have suffered because of Gadolinium Contrast Dye. Rest assured you will have Mr. Padove's commitment to defend your legal rights for the injuries you sustain due to nephrogenic systemic fibrosis and nephrogenic fibrosing dermopathy.

Call Burton Padove for a free consultation at 219-836-2200 or 877-446-5294 for nationwide callers. Visit www.todayslawalert.com to view Burton Padove's blog.